{"id":37965,"date":"2026-07-07T21:46:59","date_gmt":"2026-07-07T21:46:59","guid":{"rendered":"https:\/\/selmiswiss.com\/?post_type=product&#038;p=37965"},"modified":"2026-07-07T22:11:48","modified_gmt":"2026-07-07T22:11:48","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/selmiswiss.com\/en\/product\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"<div class=\"selmi-peptide-sheet\">\n<div class=\"selmi-peptide-header\">\n<div class=\"selmi-peptide-title\">Tirzepatide<\/div>\n<div class=\"selmi-peptide-category\">Diabetes \/ Weight Loss<\/div>\n<\/p><\/div>\n<div class=\"selmi-peptide-grid selmi-peptide-grid-top\">\n<section class=\"selmi-peptide-main\">\n<div class=\"selmi-peptide-section\">\n<h3>MECHANISM OF ACTION<\/h3>\n<p>Dual GIP\/GLP-1 receptor coagonist, with a GIP-based mechanism. Activation of the GIPR potentiates insulin, suppresses glucagon, promotes direct lipolysis in adipocytes, and modulates the central nervous system. GLP-1R promotes satiety, delays gastric emptying, and stimulates glucose-dependent insulin secretion. The C20 diacid fatty acid chain extends the half-life to approximately 5 days with weekly administration.   <\/p>\n<\/p><\/div>\n<div class=\"selmi-peptide-section\">\n<h3>KEY BENEFITS<\/h3>\n<ul>\n<li>Body weight reduction of up to 22.5% in SURMOUNT-1.<\/li>\n<li>A 2.0\u20132.3% reduction in HbA1c in the SURPASS program.<\/li>\n<li>Superior glycemic control compared with semaglutide in a direct comparative trial.<\/li>\n<li>Reduction in triglycerides and LDL.<\/li>\n<li>Improvement in sleep apnea in the SURMOUNT-OSA trial.<\/li>\n<li>Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.<\/li>\n<\/ul><\/div>\n<\/section>\n<aside class=\"selmi-peptide-dosing\">\n<h3>THE RESULTS DESCRIBED WERE OBTAINED BY FOLLOWING THE DOSAGE AND PROTOCOL SET FORTH BELOW<\/h3>\n<h4>2.5 mg\/week \u2192 up to 15 mg for 20 weeks<\/h4>\n<p><strong>Vial size:<\/strong><br \/>10 mg<\/p>\n<p><strong>Frequency:<\/strong><br \/>Once a week<\/p>\n<p><strong>IU \/ Dose:<\/strong><br \/>50 IU = 2.5 mg initial dose<\/p>\n<p><strong>Reconstitution:<\/strong><br \/>Reconstitute with 2 mL of bacteriostatic water. 50 IU = 2.5 mg initial dose. Administer monthly.  <\/p>\n<p><strong>Cycle:<\/strong><br \/>Chronic use according to the metabolic protocol.<\/p>\n<\/aside><\/div>\n<div class=\"selmi-peptide-grid selmi-peptide-grid-info\">\n<section class=\"selmi-peptide-box\">\n<h3>SIDE EFFECTS AND SAFETY<\/h3>\n<p>Gastrointestinal effects such as nausea, vomiting, and diarrhea. Class warning regarding C-cell thyroid tumors. Risk of pancreatitis. Dose titration is essential. Monitor renal function if gastrointestinal effects occur.   <\/p>\n<\/section>\n<section class=\"selmi-peptide-box selmi-peptide-box-alt\">\n<h3>RESEARCH AND CLINICAL NOTES<\/h3>\n<p>SURPASS-2, a head-to-head trial against semaglutide: tirzepatide was superior in both HbA1c and body weight. SURMOUNT-1: 22.5% reduction in body weight. Dual-action peptide approved by the FDA for dual indications, marketed as Mounjaro and Zepbound. Second-largest commercial impact after semaglutide.   <\/p>\n<\/section><\/div>\n<section class=\"selmi-peptide-profile\">\n<h3>TARGET PROFILE:<\/h3>\n<p><em>Metabolic medicine, endocrinology, bariatric medicine, and weight loss.<\/em><\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<div class=\"selmi-div-disclaimer\"><span class=\"selmi-disclaimer-text\">FOR PRECLINICAL RESEARCH USE ONLY \u2014 NOT APPROVED FOR HUMAN USE.<\/span><\/div>\n<ul>\n<li>Body weight reduction of up to 22.5% in SURMOUNT-1.<\/li>\n<li>A 2.0\u20132.3% reduction in HbA1c in the SURPASS program.<\/li>\n<li>Superior glycemic control compared with semaglutide in a direct comparative trial.<\/li>\n<li>Reduction in triglycerides and LDL.<\/li>\n<li>Improvement in sleep apnea in the SURMOUNT-OSA trial.<\/li>\n<li>Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.<\/li>\n<\/ul>\n","protected":false},"featured_media":37974,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[1115],"product_tag":[1101],"class_list":["post-37965","product","type-product","status-publish","has-post-thumbnail","product_cat-obesity-metabolism-peptides","product_tag-peptides","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product\/37965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/comments?post=37965"}],"version-history":[{"count":2,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product\/37965\/revisions"}],"predecessor-version":[{"id":37979,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product\/37965\/revisions\/37979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/media\/37974"}],"wp:attachment":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/media?parent=37965"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product_brand?post=37965"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product_cat?post=37965"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product_tag?post=37965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}